Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?

Phase 3

Completed

Conditions: Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia

First Posted Date: 1999-10-28

Last Posted Date: 2013-12-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000473

Evaluation of SC-V Versus Conventional CPR

Phase 3

Completed

Conditions: Cardiovascular Diseases
Myocardial Infarction
Arrhythmia
Heart Arrest
Cerebral Anoxia
Heart Diseases
Ventricular Fibrillation

First Posted Date: 1999-10-28

Last Posted Date: 2013-11-26

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000502

Activity Counseling Trial (ACT)

Phase 3

Completed

Conditions: Heart Diseases
Cardiovascular Diseases

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000551

Asymptomatic Cardiac Ischemia Pilot (ACIP) Study

Phase 3

Completed

Conditions: Cardiovascular Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000478

Penicillin Prophylaxis in Sickle Cell Disease (PROPS)

Phase 3

Completed

Conditions: Hemoglobinopathies
Pneumonia
Anemia, Sickle Cell
Hematologic Diseases
Infection (S. Pneumoniae)

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000585

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

Phase 3

Completed

Conditions: Respiratory Distress Syndrome, Adult
Lung Diseases

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000579

Locations: 🇺🇸
Baystate Medical Center, Springfield, Massachusetts, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Wake Forest University, Winston-Salem, North Carolina, United States

and more 18 locations

Harvard Atherosclerosis Reversibility Project (HARP)

Phase 2

Completed

Conditions: Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia

First Posted Date: 1999-10-28

Last Posted Date: 2016-03-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000461

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Phase 3

Completed

Conditions: Hypercholesterolemia
Diabetes Mellitus, Type 2
Hypertension
Diabetes Mellitus
Coronary Disease
Atherosclerosis
Cardiovascular Diseases

Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin
Drug: Anti-hyperglycemic Agents
Drug: Anti-hypertensive Agents

First Posted Date: 1999-10-28

Last Posted Date: 2016-11-22

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 10251

Registration Number: NCT00000620

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Veterans Affairs, Memphis, Tennessee, United States
🇨🇦
McMaster University, Hamilton, Ontario, Canada

and more 4 locations

Optimal Exercise Regimens for Persons at Increased Risk

Phase 2

Completed

Conditions: Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases

First Posted Date: 1999-10-28

Last Posted Date: 2005-06-24

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000523

Beta-Blocker Heart Attack Trial (BHAT)

Phase 3

Completed

Conditions: Cardiovascular Diseases
Death, Sudden, Cardiac
Coronary Disease
Heart Diseases
Myocardial Infarction
Ventricular Fibrillation
Myocardial Ischemia
Arrhythmia

First Posted Date: 1999-10-28

Last Posted Date: 2016-07-12

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000492

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy